Why Your Insurance Makes You Try Avastin Before Eylea for Diabetic Macular Edema
Avastin Before Eylea at a Glance
Your health plan is using a rule called step therapy. It asks you to try the cheaper drug first. Avastin costs about $70 a dose. Eylea costs about $1,806 a dose1. Both drugs block the same protein that makes your retina leak fluid23. So the plan wants proof that the low-cost drug is not enough before it pays for the high-cost one.
This is a money rule, not a verdict on your eye. It does not mean your doctor thinks Avastin is best for you. It means the plan has set the order of the first tries.
Starting with Avastin is a reasonable place to begin for many people. In a trial that tested this exact order, adults with moderate vision loss who started on Avastin and moved to Eylea when their eye did not respond well saw about the same vision gain after two years as adults who used Eylea the whole time4. The average gain was 14.0 letters with the Avastin-first plan and 15.0 letters with Eylea alone, and five letters make one line on the eye chart.
It does mean your visits matter. The rule only works safely if someone is checking your eye and ready to switch you. Keep every appointment, and speak up when your vision changes.
You have a few useful steps, none needing a fight on day one.
- Ask what your starting vision is, and whether it puts you where the two drugs performed alike.
- Ask what the office will measure at each visit to decide if Avastin is working.
- Ask how fast the office can request an exception if the answer is no.
- Keep your appointments, even the routine ones.
What Avastin and Eylea Are and How They Work Inside the Eye
Diabetic macular edema is swelling in the center of your retina. Diabetes damages the tiny blood vessels in the retina until they leak fluid into the macula, the small central patch you use for reading and faces5. That blurs the center while your side vision stays clear, so the change can feel oddly specific.
About 1 in 15 people with diabetes develops this swelling, and more than half of people with diabetes develop some diabetic retinopathy over their lifetime5. Those numbers are also why this treatment is so well studied: retina clinics do it daily, and the fluid usually responds once treatment starts.
Avastin is the brand name for bevacizumab, a drug that blocks vascular endothelial growth factor, usually shortened to VEGF. VEGF is the signal that drives abnormal, leaky vessels, and blocking it in the eye is standard care for diabetic eye disease and wet macular degeneration2. It is given as a small injection into the eye after numbing drops.
Avastin is not FDA-approved for any eye condition; the FDA approved bevacizumab for cancer, and eye doctors use it off-label, a legal and common practice when the evidence supports it2. Because the cancer vial is far larger than an eye dose, a compounding pharmacy divides it into single-dose syringes.
Eylea is the brand name for aflibercept, a different VEGF blocker built as a molecular trap. Eylea is FDA-approved for diabetic macular edema, and the labeled schedule is 2 mg injected into the eye every 4 weeks for the first 5 injections, then once every 8 weeks3. Your own schedule may differ, because retina doctors stretch or shorten intervals based on what your scans show.
That label is the difference your insurer sees: one drug is approved for your diagnosis, and the other is not.
Both drugs work on the same pathway, which is why a plan can argue they are close enough to try in order. Think of them as two keys cut for the same lock, one a little sturdier. Aflibercept binds VEGF more tightly and blocks a related signal too.
That edge shows up in some eyes and not in others, which the trials below tried to pin down.
How Insurance Step Therapy Works for Eye Injections
Step therapy is a coverage rule, not a medical one. It requires you to try and fail the plan's preferred medication before the plan will cover a different one, and health plans began applying it to eye injections given in the office after Medicare Advantage plans were allowed to use it for Part B drugs in 20196. For diabetic macular edema, the preferred drug is almost always bevacizumab.
The word 'fail' is doing unfortunate work here. It means your eye did not improve enough by an agreed measure, not that you did anything wrong.
Federal rules set limits on how a Medicare Advantage plan may use this tool. A plan may apply step therapy only to new administrations of a Part B drug, using a lookback period of at least 365 days, and its pharmacy and therapeutics committee must base the policy on the strength of the scientific evidence and standards of practice and must review its exception processes7.
The lookback matters to you. If you have been getting Eylea within the past year, the rule is generally not meant to pull you back onto a different drug.
Plans want an objective record, and the trial that tested this order used a clear definition. In that trial, an eye could move from bevacizumab to aflibercept starting at week 12 when swelling in the center of the retina persisted, the eye had received enough bevacizumab already, vision was still below a set level, and neither the vision nor the retinal thickness had improved enough over the prior visits4.
Your clinic tracks three things: your eye chart score, your scan measurement, and how many injections you have had. Ask to see those numbers at each visit.
You do not have to wait for the rule to run its course. Ophthalmologists commonly respond to these policies by filing an exception request or asking for a peer-to-peer conversation with the plan's medical director, and the resulting back-and-forth can delay treatment6. Starting the paperwork early beats starting it after a denial.
Plans tend to accept a documented poor response, a bad reaction to the drug, or a medical reason it is a poor fit. Your doctor's office knows the language your plan wants, so ask them to lead.
Avastin and Eylea Side by Side for Diabetic Macular Edema
These are the practical differences that drive the insurance rule.
| What differs | Avastin (bevacizumab) | Eylea (aflibercept) |
|---|---|---|
| FDA status for eye use | Off-label; approved for cancer, not for the eye | Approved for diabetic macular edema |
| Medicare cost per dose, 2022 | About $69.72 | About $1,806.00 |
| How the syringe is made | Divided from a larger vial by a compounding pharmacy | Supplied by the manufacturer as an eye dose |
| Usual early schedule | Often about every 4 weeks at first | Every 4 weeks for 5 doses, then every 8 weeks |
Cost figures come from Medicare payment data, not your out-of-pocket price1. The Eylea schedule comes from its prescribing information3.
The honest differences are narrower than the price gap suggests. Aflibercept averaged more vision gain than bevacizumab in eyes that started with moderate vision loss8, and it is approved for this diagnosis, which makes coverage simpler.
What the two share matters more day to day: the same injection, the same visit rhythm, and similar eye risks. Neither repairs damage already done, and neither is a one-time fix.
Your starting vision is the useful dividing line here, not your preference between brand names.
| Your starting vision | What the two-year trial evidence suggests |
|---|---|
| 20/32 to 20/40 (mild loss) | Average gains were similar across drugs |
| 20/50 to 20/320 (moderate loss) | Aflibercept averaged more gain than bevacizumab when used alone; starting with bevacizumab and switching when needed came out even |
These are group averages, not a forecast for your eye84. Your doctor also weighs your scan, your other eye, and your travel.
What the Head-to-Head Trials Found About Starting With Avastin
The first large head-to-head trial compared all three eye injections directly. Among 660 participants, average vision gain at two years was 12.8 letters with aflibercept, 10.0 letters with bevacizumab and 12.3 letters with ranibizumab; in eyes that started at 20/32 to 20/40 the gains of 7.8, 6.8 and 8.6 letters did not differ significantly, while in eyes starting at 20/50 to 20/320 aflibercept averaged 18.1 letters against 13.3 letters for bevacizumab8.
Read that as one finding with two halves. If your vision loss is mild, the drugs performed alike on average. If it is worse, the costlier drug had an edge alone.
A later trial tested the exact sequence your plan is asking for. Across 312 eyes in 270 adults at 54 sites, all starting at 20/50 to 20/320, average vision improvement over two years was 15.0 letters with aflibercept alone and 14.0 letters with bevacizumab first, an adjusted difference of 0.8 letters with a statistical range from -0.9 to 2.5 letters that includes no difference at all; about 70 of every 100 bevacizumab-first eyes were switched4.
That is the study your insurer leans on, and its result is reassuring on one condition: the switch has to happen when the eye asks for it. Eyes that met the switch criteria and moved to aflibercept gained about 3.7 letters of vision on average after the change9.
Averages hide individual stories. Some eyes clear on bevacizumab and never need anything else. Others hold fluid until the drug changes. A one-letter average describes neither.
The trials also ran on strict visit schedules that real life rarely matches. Miss visits, and the safety net that makes a start-cheap plan reasonable is the first to go.
Costs, Risks, and a Realistic Outlook
The price gap is the engine of this policy. Using 2022 Medicare payment data, one dose of bevacizumab ran about $69.72 and one dose of aflibercept about $1,806.00, and modelled two-year costs per patient were about $18,952 for the bevacizumab-first approach against about $31,964 for aflibercept alone1.
Your own share is a different number. Under Medicare Part B, coinsurance is usually a share of the drug's cost, so a cheaper drug can mean a smaller bill. Ask your clinic's billing staff to estimate both before deciding the fight is worth having.
The risks belong to the injection far more than to the choice of drug. Common effects include red or itchy eyes, temporary blurring and floaters, and rare serious problems include infection inside the eye and retinal detachment2. Serious injection-related reactions of that kind occurred in fewer than 1 of every 1,000 injections in the Eylea prescribing information3.
Pooled analyses of eye injections found infection inside the eye in 197 of 350,535 injections in one analysis and 52 of 105,536 in another, with symptoms usually starting 1 to 6 days later10. Those odds are low, and the response is simple: call the same day if your eye becomes painful or your vision drops, because early treatment gives the eye its best chance.
The risk in step therapy is not the first drug. It is the wait between the day your eye stops responding and the day the second drug arrives. The trial that tested this order built its switch rule in from week 12 rather than leaving the wait open-ended4.
You can shrink that gap. Keep the visits, report new blur promptly, and ask your clinic to file the exception request the week you meet the criteria.
For most people, these injections are long-running control rather than a short course. In the trials above, average vision improved by roughly two to three lines on an eye chart over two years, with injections continuing throughout4. Some gain more, some less, and some hold steady, which is a good result when the alternative is ongoing loss.
Blood sugar and blood pressure control still do heavy lifting. Injections treat the leaking; the rest of your diabetes care sets how hard they must work.
When to Call Your Eye Doctor Between Injections
Most soreness after an injection fades within a day, and a gritty or bloodshot eye is expected. A few problems need care right away.
- Eye pain that gets worse rather than better after the first day
- Vision that drops noticeably in the treated eye
- Growing redness with light sensitivity
- A sudden shower of new floaters, flashing lights, or a curtain or shadow across your sight
The Eylea prescribing information instructs patients and caregivers to report any sign or symptom suggesting infection inside the eye or retinal detachment without delay3. Infection after an injection usually announces itself 1 to 6 days later with eye pain in about 74 of every 100 cases and redness in about 82 of every 100, alongside falling vision10. Treated quickly, many eyes do well, which is why the same-day call matters.
Some changes are not emergencies, but they should not wait months for a scheduled slot. Call within a few days if reading gets harder, if straight lines bend, or if a blurred patch in the center grows.
These are also the signs that your eye may be asking for a switch. Reporting them early protects your vision and builds the record your exception request needs.
These injections are given by an ophthalmologist, usually a retina specialist. Your optometrist or primary care doctor may be the one who spots the swelling and sends you on.
Ask for a retina referral, or a second opinion, if nobody is scanning your macula or explaining when a switch would happen.
Questions People Ask About Starting on Avastin
No. They are different molecules that block the same growth signal, and Avastin has been used in eyes since 20052. In head-to-head testing, aflibercept averaged more vision gain in eyes with moderate vision loss, while eyes with mild loss did about as well on either drug8. Cheaper reflects how the drug is made and sold, not a weaker formula.
Generally yes, within limits. Federal rules let a Medicare Advantage plan apply step therapy to Part B drugs, but only to new administrations, using a lookback of at least 365 days, with a committee that must ground the policy in scientific evidence and review its exception processes7. Commercial plans set their own versions. You keep the right to request an exception.
The trial built to answer this found no meaningful difference at two years between starting on aflibercept and starting on bevacizumab with a switch when the eye did not respond4. That approach rests on the switch happening on time. Keeping every visit, and speaking up when vision changes, is what keeps a delay from becoming a loss.
There is no single number, and your plan's paperwork rather than a law sets it. In the trial that tested this order, eyes became eligible to switch from week 12 onward when swelling persisted and neither vision nor retinal thickness had improved enough after adequate treatment4. Ask your clinic to show you the criteria your own plan uses.
On average, yes. In eyes starting at 20/32 to 20/40, average two-year gains were 6.8 letters with bevacizumab, 7.8 with aflibercept and 8.6 with ranibizumab, and those differences were not statistically significant8. Mild starting loss is where the case for the costly drug is weakest. Your own response still needs checking at every visit.
The extra step is real, and it is why sourcing matters. A cancer vial is divided into eye-sized doses before it reaches your clinic. Reported eye risks for bevacizumab, including the rare infection inside the eye, are in the same range as those of other eye injections210. It is fair to ask your clinic where its syringes come from.
More Questions About Switching, Costs, and Appeals
Ask your retina office to file a formal exception request with your response documented, then ask for a peer-to-peer discussion with the plan's medical director if that request is denied6. Get the denial in writing, note the appeal deadline, and ask what treatment you get while the appeal runs.
Often yes, because coinsurance under Medicare Part B is usually a share of the drug's cost, and the two run roughly $69.72 against $1,806.00 per dose in 2022 Medicare data1. Supplemental coverage, Medicaid, or a manufacturer assistance program can change that math a lot. Ask your clinic's billing staff to estimate both.
It is possible, though the cost is steep at roughly $1,806.00 per dose in 2022 Medicare data, before clinic and visit fees1, and treatment usually runs a year or more. First ask whether your eye already meets the switch criteria, because if it does, an exception request may get the same drug covered within days.
Usually not. Medicare Advantage step therapy applies to new administrations of a Part B drug and uses a lookback of at least 365 days, so ongoing treatment is generally outside its reach7. If you switch plans and get a letter suggesting otherwise, tell your retina office so they can document your history.
Bring these to your next injection visit and write down the answers.
- What is my vision measurement and my retinal thickness today, and how have they changed?
- Does my starting vision put me in the group where the drugs performed similarly?
- What will you use to decide that Avastin is not working for me?
- When that point comes, who files the exception request and how long does it take?
- What should I do between visits if my vision changes?
- Where does this clinic get its bevacizumab syringes?
- What is my estimated out-of-pocket cost for each drug?
- Journal of Vitreoretinal Diseases, full text via PubMed Central (2024). Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis.
- American Academy of Ophthalmology, EyeSmart patient education (reviewed by Veena R. Raiji, MD) (2026). What Is Avastin?.
- DailyMed, U.S. National Library of Medicine (label revised October 2024) (2024). EYLEA (aflibercept) injection, solution: FDA-approved prescribing information.
- New England Journal of Medicine (Jhaveri CD, Glassman AR, Ferris FL 3rd, et al.), full text via PubMed Central (2022). Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema (DRCR Retina Network Protocol AC).
- National Eye Institute, National Institutes of Health (2025). Diabetic Retinopathy.
- American Academy of Ophthalmology, EyeNet Magazine (2022). Step Therapy: Clinicians' Concerns and Challenges.
- U.S. Code of Federal Regulations, via GovInfo (2023). 42 CFR 422.136, Medicare Advantage (MA) and step therapy for Part B drugs.
- Ophthalmology (Wells JA, Glassman AR, Ayala AR, et al.), PubMed record 26935357 (2016). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial (DRCR Protocol T).
- Ophthalmology (secondary analysis of DRCR Protocol AC), PubMed record 38336282 (2024). Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of Less Than 20/40.
- Graefe's Archive for Clinical and Experimental Ophthalmology, full text via PubMed Central (2022). Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.